Takeda Pharmaceutical : Announces Candidates for New Directors

News Release

Takeda Announces Candidates for New Directors

OSAKA, Japan, March 31, 2021, --- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced candidates for its Board of Directors that will be proposed at the 145th Ordinary General Meeting of Shareholders to be held on June 29, 2021.

Proposed Change in Directors

Takeda is committed to exercising strong corporate governance practices to promote the long-term interests of shareholders and all its stakeholders as well as strengthening its Board of Directors and management accountability. As part of this commitment, the Board of Directors decided that all members of the Audit and Supervisory Committee will be external directors to further enhance the independence of the Committee. Mr. Yasuhiko Yamanaka, Director, a member of the Audit and Supervisory Committee will retire from his current role effective upon the conclusion of the 145th Ordinary General Meeting of Shareholders and become an advisor for one year to ensure smooth transition to the Committee consisting of fully external Directors.

Also, Takeda is pleased to nominate Mr. Masami Iijima from Mitsui & Co., Ltd. to join as an External Director who will be a substitute member of the Audit and Supervisory Committee. Joining Mitsui & Co., Ltd. in 1974, Mr. Iijima has held various senior roles of increasing responsibility, and recently served as Representative Director, Chairman of the Board of Directors. He will continue serve as Director until June 18 when he will be nominated as Counselor. Mr. Masami IIjima is also currently serving as External Director for Ricoh Company, Ltd., SoftBank Group Corp., and Isetan Mitsukoshi Holdings Ltd., as well as Counsellor of Bank of Japan.

As already announced, Mr. Masato Iwasaki, who started with Takeda in 1985, will transition from the role of president of Japan Pharma Busines Unit to the role of Japan General Affairs on April 1, 2021. Further, the Board of Directors has resolved that upon Mr. Iwasaki's election as a Director at the 145th Ordinary General Meeting of Shareholders, he will then be appointed as another Representative Director at a Board of the Directors meeting immediately following the 145th Ordinary General Meeting of Shareholders. In his new role as Japan General Affairs, Mr. Iwasaki will chair and coordinate a network representing all of Takeda's functions in Japan to maintain and enhance the Company's reputation in Japan and to ensure one voice to our external stakeholders in Japan.

1

Candidates for Directors Who are Not Audit and Supervisory Committee Members

	Name	Category	Expected Role
	Christophe Weber	Internal	Existing	Representative Director,
	President & Chief Executive Officer
	Masato Iwasaki	Internal	Existing	Representative Director, Japan General Affairs
	Andrew Plump	Internal	Existing	Director, President, Research & Development
	Constantine Saroukos	Internal	Existing	Director, Chief Financial Officer
	Masahiro Sakane	External	Existing	External Director, Chair of the Board Meeting
	Chair of the Nomination Committee
	Olivier Bohuon	External	Existing	External Director
	Member of the Compensation Committee
	Jean-Luc Butel	External	Existing	External Director
	Member of the Nomination Committee
	Ian Clark	External	Existing	External Director
	Member of the Compensation Committee
	Yoshiaki Fujimori	External	Existing	External Director
	Member of the Compensation Committee
	Steven Gillis	External	Existing	External Director
	Member of the Nomination Committee
	Shiro Kuniya	External	Existing	External Director
	Toshiyuki Shiga	External	Existing	External Director
	Member of the Nomination Committee
Candidate for Director Who is Audit and Supervisory Committee Member

Name	Category	Expected Role
Masami Iijima	External New	External Director, Audit and Supervisory Committee
Member

The following three Directors who are Audit and Supervisory Committee members were elected at the 144th Ordinary General Meeting of Shareholders held in 2020 and their terms of office will continue until the 146th Ordinary General Meeting of Shareholders held in 2022.

2

Name	Category	Role
Koji Hatsukawa	External	Existing	External Director, Chairperson of Audit and
Supervisory Committee
			External Director, Audit and Supervisory Committee
Emiko Higashi	External	Existing	Member
			Chair of the Compensation Committee
			External Director, Audit and Supervisory Committee
Michel Orsinger	External	Existing	Member
			Member of the Nomination Committee

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)is a global, values-based,R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

Media Contacts:

Japanese Media Kazumi Kobayashi [e-mail] [phone]

Media Outside Japan Holly Campbell [e-mail] [phone]

###

3

Attachment

Takeda To Appoint Another Representative Director

As detailed below, Takeda Pharmaceutical Company Limited ("Takeda") today announced that its Board of Directors has resolved to appoint another Representative Director at a Board of the Directors meeting immediately following the 145th Ordinary General Meeting of Shareholders where Directors who are not members of the Audit and Supervisory Committee are to be elected to the Board of Directors on June 29, 2021.

1. Reason for the appointment
   Takeda has decided to establish a new role to chair and coordinate a network representing all Takeda's functions in Japan to maintain and enhance its reputation in Japan and to ensure one voice to its external stakeholders in Japan.
2. Name and title of new representative director

Name		New Role (anticipated effective date, June 29, 2021)	Prior Role (appointed on April 1, 2021)
Masato Iwasaki		Representative Director, Japan General Affairs	Director, Japan General Affairs
3. Career summary of new representative director
Date of birth	Career summary, and position and responsibilities at the Company	Number of
shares owned
November 6,	April 1985	Joined the company		45,996 shares
1958	April 2008	Senior Vice President, Strategic Planning Department of the
			Company
	January 2012	Head of CMSO Office, Takeda Pharmaceuticals
			International Inc.
	April 2012	Senior Vice President, Pharmaceutical Marketing Division
			of the Company
	June 2012	Director of the Company (to present)
	April 2015	President, Japan Pharma Business Unit of the Company
	April 2021	Japan General Affairs

4. Anticipated Effective Date June 29, 2021

###

4